SGHT

Several significant events impacted Sight Sciences' stock in the past six months. In Q3 2025, the company reported a slight revenue decrease but an increase in Surgical Glaucoma revenue, along with reduced operating expenses. In Q4 2025, Sight Sciences reported a revenue increase and a high gross margin, initiating full-year 2026 revenue guidance. A U.S. District Court issued an order preserving a jury's verdict that Alcon willfully infringed three of Sight Sciences' patents, awarding monetary damages and an ongoing royalty. In Q1 2026, the company reported a revenue increase driven by growth in both Interventional Glaucoma and Interventional Dry Eye, with a strong gross margin and reduced cash usage, raising its full-year 2026 revenue guidance. SGHT stock has traded between $2.81 and $9.24 over the past 52 weeks, with a stock price of $4.30 as of May 6, 2026.